OBJECTIVE -To evaluate facility rankings in achieving Ͻ7% A1C levels based on the complexity of glycemic treatment regimens using threshold and continuous measures.
T
he National Committee for Quality Assurance (NCQA)-Healthcare Employer Information Data Set (HEDIS) measure for good (Ͻ7% A1C) glycemic control was revised in 2009 to apply only to individuals Ͻ65 years without cardiovascular diseases, end-stage diabetes complications, or dementia (1). Although most patients will require the use of insulin to achieve tight control within 10 years of diagnosis (2), even short-term attainment of an A1C level Ͻ7% may be difficult for such individuals (3,4). In a representative sample of the U.S. population, receipt of insulin resulted in a 14% decrease in the number of individuals attaining a Ͻ7% threshold (5). Because the frequency and risk of hypoglycemia may be a concern (6), multiple guidelines recommend that glycemic control targets should be individualized for such individuals, especially in the presence of comorbid medical and mental health conditions (7). Furthermore, individuals with diabetes may choose not to initiate insulin for suboptimal glycemic control even when recommended (8). Thus, any performance measure, especially one used for public reporting or provider payment, should take into account case mix differences among populations. Although there are no validated risk adjustment models for glycemic control, one potential indicator of case mix is the type and complexity of the medication regimen used (5).
The Veterans Health Administration (VHA) is the nation's largest integrated health care system and has national data repositories of individual administrative, pharmacy, and laboratory records (9). Our study objective was to compare changes in facility-level rankings based on the NCQA-HEDIS measure, as currently specified, with rankings based on a subset of patients receiving either insulin or three oral agents. We hypothesized that the identification of "best" and "worse" performing facilities would differ between these groups. Additional objectives were to compare rankings using the threshold measure with those using a continuous measure that awarded incremental credit for improvement between 7.9% and Ͻ7.0% A1C (10), and to evaluate the impact of excluding additional serious medical and mental illnesses.
RESEARCH DESIGN AND METHODS

Data sources and patient identification
Inpatient and outpatient utilization data, ICD-9-CM codes, and diagnostic codes were obtained from the National Patient Clinical Dataset (Austin, TX), laboratory data was obtained from the Decision Support System, and medication data were from the Pharmacy Benefits Management Program (11 Patients were defined as having a complex glycemic regimen (CGR) if they were receiving either insulin or three oral agents. Such patients would be considered to have received maximal oral agent therapy, especially if they were receiving thiazolidinediones. During this period, the VHA Pharmacy Benefits Management (12) classified thiazolidinediones as third-line therapy and facilities monitored their usage.
Denominator exclusion criteria
The denominator for the primary analyses was based on current NCQA-HEDIS criteria that exclude individuals with cardiovascular conditions, end-stage complications of diabetes (blindness, amputations, and end-stage renal disease), and dementia based on one ICD9-CM or Current Procedural Terminology (CPT) code in either the calendar year or preceding year (1). To evaluate the impact of other chronic illnesses on facility rankings, we similarly identified and excluded patients in the NCQA denominator for conditions in the following categories, as previously described (13) and/or increased risk from intensive treatment (7).
Analysis
We evaluated the distributions of glycemic control for all patients in the NCQA denominator, as well as for patients stratified by CGR and non-CGR status (using both 0.1% A1C increments and ordinal intervals). At the facility level, we determined the proportion of patients who achieved Ͻ7% A1C based upon the last A1C test in FY04 within the specified denominators. To increase the reliability of facility rankings, we specified that a facility must have at least 100 patients receiving CGRs (14) .
In addition to the use of the NCQA measure, we also evaluated the use of a continuous measure that would provide partial credit for A1C values between 7.9 and 7.0% and full (100%) credit for values Ͻ7.0% (10). In contrast, a threshold measure (such as Ͻ7% A1C) awards 100% credit only for values Ͻ7% and no credit for any values Ն7%. In brief, because the lifetime absolute risk reduction of microvascular complications resulting from lower A1C is linear within this range (as opposed to a log-linear absolute risk reduction when starting at higher A1C levels), arithmetic interpolation was used to equally weight each 0.1% decrease in A1C.
Facility rankings were determined by assigning facilities into five ordinal categories based on both z score distribution (Յ10% [five stars or best], 10 -33% [four stars], 34 -66% [three stars], 67-90% [two stars], and Ն90% [one star or worst]) and statistical significance (P Ͻ 0.05) (15) . Statistical significance was calculated using the interval as follows:
(Facility rate Ϫ Overall mean rate)
Significance was assumed if the interval did not include zero. Differences in ranking were assessed using the Spearman correlation coefficient and movement of facilities between the categories. The study was approved by the institutional review boards of the East Orange and Cleveland VA Medical Centers. The A1C distributions were similar for the NCQA and non-CGR denominators but differed markedly for the CGR denominator (Fig. 1) . Of the patients not receiving CGRs, 56.0% had A1C values Ͻ7%, 12.6% had A1C values of 7.0 -7.4%, and 8.8% had AIC values of 7.5-7.9%, compared with 24.8, 12.2, and 12.2% for the patients receiving CGRs. Compared with the non-CGR denominator, in which 22.6% had A1C values Ͼ7.9%, there was increased skewness of the NCQA and CGR denominators, for which the proportions were 30.1 and 50.7%, respectively.
RESULTS
At the facility level, the mean and range of percent achievement of a Ͻ7% threshold varied considerably between the NCQA and CGR denominators for each ranking category (Table 2) . For example, the top 10% performing facilities overall achieved a rate of 57% (range 54 -62%) compared with 34% (31-38%) for individuals receiving CGRs. The use of a continuous measure increased the percent achievement compared with the dichotomous measure by 12% for both the overall and CGR denominator. There was an overall 1.2% lower achievement for the denominator that used additional exclusion criteria (data not shown).
The overall correlation of facility rankings using the NCQA measure with the CGR denominator was 0.61 and in a sensitivity analysis was 0.65 for A1C Ͻ7.5% and 0.74 for A1C Ͻ8%. The correlation was 0.97 with the additional exclusion criteria denominator. Rankings of both the aggregate and CGR denominators using the dichotomous threshold were comparable to those using a continuous measure (0.96 and 0.90).
However, the identification of best and worst facilities differed markedly between the NCQA denominator (all patients) and the CGR denominator (Table  3) . In this comparison, 8 of 24 facilities that were statistically different identified as being best (five stars) or worst (one star) using the NCQA measure became not significantly different (three stars), and an additional 5 of 24 moved up in ranking. Overall, 42 of 68 (62%) facilities ranked statistically better or worse using the NCQA denominator were ranked as average (not statistically different) using the CGR denominator; 12 of 59 (20%) ranked average became significantly higher or lower. Six of the 31 four-or five-star ranked facilities were ranked lower when exclusion criteria for significant comorbid conditions were applied.
CONCLUSIONS -We demonstrated that overall rankings of VHA facilities based on achievement of the NCQA-HEDIS Ͻ7% A1C measure as specified were only modestly correlated with rankings for the subset of patients receiving CGRs. When evaluated based on the NCQA-HEDIS practice of awarding "stars" to denote plan quality rankings, approximately two-thirds of facilities ranked best (four or five stars) overall and about 6 of 10 of those ranked worst (one or two stars) on the current measure were ranked average (three stars, not statistically different) when evaluated using the CGR denominator.
Although it is possible that the observed difference in rankings between the NCQA measure and the CGR denominator may reflect differences in quality of care provided to patients receiving more complex treatment regimens, it could also reflect patient characteristics among facilities. For example, in the current study, the facility percentage of patients receiving CGRs varied twofold (17.9 to 35.2%). In a prior study (16) , the 10th and 90th percentile of VA facilities differed mark- Furthermore, only about one-third of highly selected patients started on basal insulin (4,18) and about half using a combination of long-acting insulin and prandial insulin (3) can achieve and maintain A1C Ͻ7% over 26 -52 weeks. Frequent or severe hypoglycemia may be neither acceptable nor safe for many patients, especially those with comorbid conditions and less willingness or ability to comply with recommended self-management. Therefore, the feasibility of achieving Ͻ7% A1C in individuals with diabetes of longer duration in general clinical practice is not known.
Consequently, reliance on a Ͻ7% threshold measure as the "quality standard" for public reporting or pay for performance could have the unintended consequence of adversely affecting patient safety. Recent trials have demonstrated the potential risks of serious hypoglycemia even in patients who cannot achieve a Ͻ7% target (6), and there are significant costs associated with insulin-related hypoglycemia even among employed individuals (19) . Moreover, the true value of a single A1C test result of 7% from an accredited laboratory can be within a 6.65 to 7.35% range, assuming a permissible intra-assay coefficient of variation of 5% (20) . Point-of-care assays are even more variable, yet A1C testing in the physician office is exempt from external oversight (20) . Clinical decisions to initiate or intensify insulin need to be made on the basis of careful evaluation of individual patient trends in A1C and selfmonitoring results rather than a single A1C value that is marginally higher (i.e., within laboratory error) than the performance measure (21) . We propose that rather than assessing "good glycemic control" by an all-or-none threshold, developers should provide credit for an A1C result within an acceptable range to balance the tradeoffs of benefits, harms, and patient preferences.
Alternatively, a continuous measure that can assess incremental improvement toward an A1C Ͻ7% target for patients receiving CGRs may have significant desirable attributes over an all-or-none threshold measure with respect to relevance, scientific soundness, and feasibility. At the population level, it would provide more information for inferential hypothesis testing compared with a categorical or binomial measure (22) and could minimize statistical variation at a population level due to either A1C measurement accuracy and bias (20) or seasonal variation (23) . It is also consistent with the evolving quality improvement literature that demonstrates the difficulty in increasing attainment of Ͻ7% A1C, especially in patients with starting A1C levels Ͼ8%, despite structured interventions in staff model practice settings with electronic health care records (24) . Because it is not possible to identify type 1 diabetes or duration of disease using administrative data, stratification by treatment regimen is a pragmatic approach that can minimize attribution error; that is, better glycemic control is incorrectly interpreted as improved plan quality when it actually reflects a greater proportion of patients with recent-onset diabetes (patients not receiving CGRs) in the denominator.
In addition, from both an individual and a population health perspective, there is a greater health benefit from treating higher A1C values (Ͼ8%) than values marginally Ͼ7%. A continuous measure can better reward the additional time and costs of a multidisciplinary team approach spent on intensive therapy of patients with complex treatment regimens even if they do not reach the Ͻ7% "goal." This strategy could incentivize physician practices to compete for referrals or enter into contractual relationships with endocrinologists or disease management programs, thus focusing scarce resources on the most difficult patients with the greatest need.
Finally, although exclusion criteria had a minimal impact on rankings, we suggest that performance measure developers incorporate additional exclusion criteria that would be consistent with guideline recommendations (7). Because the current measure excludes individuals with a single cardiovascular ICD9-CM code regardless of therapy, it seems reasonable to either exclude or stratify patients with comorbid conditions that might increase the risk of serious hypoglycemia with CGRs. Further study is needed to define the sensitivity and specificity of algorithms to identify such patients.
Our study is limited by the ability to assess severity of chronic disease or patient level factors using administrative data. We also did not determine the starting point for glycemic control, medication persistence, or adverse events (including hypoglycemia). However, these are general limitations of using only administrative data for evaluation of industry standard cross-sectional measures. Additional studies are necessary to ascertain whether our findings in the VHA are generalizable to other health care systems.
In summary, the assessment of the quality of good glycemic control among Data are n or %. Within each denominator, facilities were ranked within five ordinal categories based on both z score distribution (Յ10% ͓5 stars or best͔; 10 -33% ͓4 stars͔; 34 -66% ͓3 stars͔; 67-90% ͓2 Stars͔, and Ն90% ͓1 star or worst͔) and statistical significance (P Ͻ 0.05). The minimum, maximum, and mean proportion of patients meeting the measure are presented for the facilities included within each category.
VHA facilities differs using the NCQA-HEDIS measure compared with a subset of patients receiving complex glycemic treatment regimens. Our recommendation to stratify measures by CGR and to award partial credit using a continuous measures are consistent with proposals made at a 2006 AHRQ funded conference (25) . Although the use of a single number for all enrollees to reflect the quality of glycemic treatment within a plan may be attractive in its simplicity, it is superficial and may be misleading. A lack of an appreciation of the hidden complexities of care and measurement by policy makers and managers may thus result in actions that have unintended and potentially harmful consequences for patients, providers, plans, and society.
